β-carboline compounds, including harmine, inhibit dyrk1a and tau phosphorylation at multiple alzheimers disease-related sitesβ-carboline化合物,包括骆驼蓬碱,抑制dyrk1a和τ磷酸化在多个阿尔茨海默疾病相关网站.pdfVIP

下载本文档

6
0
约5.54万字
约 9页
2017-09-12 发布于上海
举报
版权申诉

β-carboline compounds, including harmine, inhibit dyrk1a and tau phosphorylation at multiple alzheimers disease-related sitesβ-carboline化合物,包括骆驼蓬碱,抑制dyrk1a和τ磷酸化在多个阿尔茨海默疾病相关网站.pdf

1、有哪些信誉好的足球投注网站（book118）网站文档一经付费（服务费），不意味着购买了该文档的版权，仅供个人/单位学习、研究之用，不得用于商业用途，未经授权，严禁复制、发行、汇编、翻译或者网络传播等，侵权必究。。
2、本站所有内容均由合作方或网友上传，本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺！文档内容仅供研究参考，付费前请自行鉴别。如您付费，意味着您自己接受本站规则且自行承担风险，本站不退款、不进行额外附加服务；查看《如何避免下载的几个坑》。如果您已付费下载过本站文档，您可以点击这里二次下载。
3、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等，请点击“版权申诉”（推荐），也可以打举报电话：400-050-0827(电话支持时间：9:00-18:30)。
4、该文档为VIP文档，如果想要下载，成为VIP会员后，下载免费。
5、成为VIP后，下载本文档将扣除1次下载权益。下载后，不支持退款、换文档。如有疑问请联系我们。
6、成为VIP后，您将拥有八大权益，权益包括：VIP文档下载权益、阅读免打扰、文档格式转换、高级专利检索、专属身份标志、高级客服、多端互通、版权登记。
7、VIP文档为合作方或网友上传，每下载1次，网站将根据用户上传文档的质量评分、类型等，对文档贡献者给予高额补贴、流量扶持。如果你也想贡献VIP文档。上传文档

β-carboline compounds, including harmine, inhibit dyrk1a and tau phosphorylation at multiple alzheimers disease-related sitesβ-carboline化合物,包括骆驼蓬碱,抑制dyrk1a和τ磷酸化在多个阿尔茨海默疾病相关网站

b-Carboline Compounds, Including Harmine, Inhibit DYRK1A and Tau Phosphorylation at Multiple Alzheimer’s Disease-Related Sites 1,4 1,4 2 2 3 Danielle Frost , Bessie Meechoovet , Tong Wang , Stephen Gately , Marco Giorgetti , Irina Shcherbakova3, Travis Dunckley1,4* 1 Neurogenomics Division, Translational Genomics Research Institute, Phoenix, Arizona, United States of America, 2 Translational Drug Development, Translational Genomics Research Institute, Scottsdale, Arizona, United States of America, 3 MediProPharma, Inc., Salt Lake City, Utah, United States of America, 4 Arizona Alzheimer’s Research Consortium, Phoenix, Arizona, United States of America Abstract Harmine, a b-carboline alkaloid, is a high affinity inhibitor of the dual specificity tyrosine phosphorylation regulated kinase 1A (DYRK1A) protein. The DYRK1A gene is located within the Down Syndrome Critical Region (DSCR) on chromosome 21. We and others have implicated DYRK1A in the phosphorylation of tau protein on multiple sites associated with tau pathology in Down Syndrome and in Alzheimer’s disease (AD). Pharmacological inhibition of this kinase may provide an opportunity to intervene therapeutically to alter the onset or progression of tau pathology in AD. Here we test the ability of harmine, and numerous additional b-carboline compounds, to inhibit the DYRK1A dependent phosphorylation of tau protein on serine 396, serine 262/serine 356 (12E8 epitope), and threonine 231 in cell culture assays and in vitro phosphorylation assays. Results demonstrate that the b-carboline compounds (1) potently reduce the expression of all three phosphorylated forms of tau protein, and (2) inhibit the DYRK1A catalyze